SEARCH

SEARCH BY CITATION

References

  • 1
    Tillmann HL, Heiken H, Knapik-Botor A et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001; 345: 715724.
  • 2
    Shankar EM, Balakrishnan P, Vignesh R, Velu V, Jayakumar P, Solomon S. Current views on the pathophysiology of GB virus C coinfection with HIV-1 infection. Curr Infect Dis Rep 2011; 13: 4752.
  • 3
    Yeo AE, Matsumoto A, Hisada M, Shih JW, Alter HJ, Goedert JJ. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Ann Intern Med 2000; 132: 959963.
  • 4
    Sheng W-HW, Hung C-CC, Wu R-JR et al. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2007; 44: 584590.
  • 5
    Campos AF, Tengan FM, Silva SAA, Levi JE. Influence of hepatitis G virus (GB virus C) on the prognosis of HIV-infected women. Int J STD AIDS 2011; 22: 209213.
  • 6
    Antonucci G, Girardi E, Cozzi-Lepri A et al. Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals. Antivir Ther 2005; 10: 109117.
  • 7
    Bonfanti P, Capetti A, Rizzardini G. HIV disease treatment in the era of HAART. Biomed Pharmacother 1999; 53: 93105.
  • 8
    Carpenter CC, Fischl MA, Hammer SM et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996; 276: 146154.
  • 9
    Lange JM. Changing therapy in HIV. AIDS 1996; 10 (Suppl 1): S27S30.
  • 10
    Tillmann HL, Manns MP. GB virus-C infection in patients infected with the human immunodeficiency virus. Antiviral Res 2001; 52: 8390.
  • 11
    Tillmann HL, Kaiser T, Fox Z et al. Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial. J Acquir Immune Defic Syndr 2005; 40: 378380.
  • 12
    Vahidnia F, Petersen M, Stapleton JT, Rutherford GW, Busch M, Custer B. Acquisition of GB virus type C and lower mortality in patients with advanced HIV disease. Clin Infect Dis 2012; 55: 10121019.
  • 13
    Stapleton JT, Chaloner K, Martenson JA et al. GB virus C infection is associated with altered lymphocyte subset distribution and reduced T cell activation and proliferation in HIV-infected individuals. Apetrei C, editor. PLoS ONE 2012; 7: e50563.
  • 14
    Rodriguez B, Woolley I, Lederman MM, Zdunek D, Hess G, Valdez H. Effect of GB virus C coinfection on response to antiretroviral treatment in human immunodeficiency virus-infected patients. J Infect Dis 2003; 187: 504507.
  • 15
    Souza IE, Zhang W, Diaz RS, Chaloner K, Klinzman D, Stapleton JT. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians. HIV Med 2006; 7: 2531.
  • 16
    Hammer SM, Katzenstein DA, Hughes MD et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996; 335: 10811090.
  • 17
    Hirschel B. Concorde trial of immediate versus deferred zidovudine. Lancet 1994; 343: 13571358.
  • 18
    Cameron DW, Heath-Chiozzi M, Danner S et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351: 543549.
  • 19
    Schwarze-Zander C, Neibecker M, Othman S et al. GB virus C coinfection in advanced HIV type-1 disease is associated with low CCR5 and CXCR4 surface expression on CD4(+) T-cells. Antivir Ther 2010; 15: 745752.
  • 20
    Giret MTM, Kallas EG. GBV-C: state of the art and future prospects. Curr HIV/AIDS Rep 2012; 9: 2633.
  • 21
    Calza L, Manfredi R. Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection. Curr HIV Res 2012; 10: 661672.
  • 22
    Valantin MA, Lambert-Niclot S, Flandre P et al. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother 2012; 67: 691695.
  • 23
    Krajden M, Yu A, Braybrook H et al. GBV-C/hepatitis G virus infection and non-Hodgkin lymphoma: a case control study. Int J Cancer 2010; 126: 28852892.
  • 24
    Nicolosi Guidicelli S, Lopez-Guillermo A, Falcone U et al. Hepatitis C virus and GBV-C virus prevalence among patients with B-cell lymphoma in different European regions: a case-control study of the International Extranodal Lymphoma Study Group. Hematol Oncol 2011; 30: 137142.
  • 25
    Ernst D, Pischke S, Greer M, Wedemeyer H, Stoll M. No increased incidence for GB-virus C infection in a cohort of HIV-positive lymphoma patients. Int J Cancer 2011; 128: 3013; author reply 3012.
  • 26
    Williams CF, Klinzman D, Yamashita TE et al. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med 2004; 350: 981990.
  • 27
    Devereux H, Sabin CA, Kinson Z et al. Influence of HIV-1 infection on GBV-C infection in multiply infected haemophilic patients. J Med Virol 1998; 56: 316320.
  • 28
    Collazos J, Asensi V, Cartón JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS 2007; 21: 835843.
  • 29
    Cofrancesco J Jr, Scherzer R, Tien PC et al. Illicit drug use and HIV treatment outcomes in a US cohort. AIDS 2008; 22: 357365.
  • 30
    Jung S, Eichenmüller M, Donhauser N et al. HIV entry inhibition by the envelope 2 glycoprotein of GB virus C. AIDS 2007; 21: 645647.
  • 31
    Stapleton JT, Chaloner K, Zhang J et al. GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS 2009; 23: 605610.